CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Harrow Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Harrow Inc
102 WOODMONT BLVD, SUITE 610
Phone: (615) 733-4731p:615 733-4731 NASHVILLE, TN  37215  United States Ticker: TDLP TDLP
Business Summary
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
1400 Mining and quarrying of nonmetallic minerals, except fuels
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Mark L.Baum 51 8/19/2021 12/16/2011
Chief Financial Officer, Corporate Secretary Andrew R.Boll 41 2/1/2015 2/1/2012
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer John P.Saharek 64 1/2/2024 2/1/2015
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Aerosol Science Laboratories, Inc. 900 Calle Plano, Suite M Camarillo CA United States
IMPRIMIS RX 9257 RESEARCH DR IRVINE CA
Sinutopic, Inc. 755 Lakefield Rd., Unit D Westlake Village CA United States
PHARMACY CREATIONS LLC 540 STATE ROUTE 10 STE 3 RANDOLPH NJ
Topical Apothecary Group, LLC 780 Primos Ave., Unit E Folcroft PA United States

Business Names
Business Name
Aerosol Science Laboratories, Inc.
ASL Pharmacy
Bywater Resources, Inc.
19 additional Business Names available in full report.

General Information
Number of Employees: 315 (As of 3/1/2024)
Outstanding Shares: 35,614,718 (As of 11/12/2024)
Shareholders: 67
Stock Exchange: NASD
Federal Tax Id: 450567010
Fax Number: (858) 345-1745


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024